Neurokognitive Effekte häufig in der Epilepsiebehandlung eingesetzter Antiepileptika

I. Oppenheim; B. Brunner; A. Pöpel; G. Krämer; H. Jokeit

doi:10.1055/s-0028-1090129

Aktuelle Neurologie 2009; 36(1): 19-29
DOI: 10.1055/s-0028-1090129

Übersicht

Neurokognitive Effekte häufig in der Epilepsiebehandlung eingesetzter Antiepileptika

Neurocognitive Effects of Antiepileptic Drugs Frequently Used in Long-Term Treatment of Epilepsies: A ReviewI. Oppenheim¹ , B. Brunner¹ , A. Pöpel¹ , G. Krämer¹ , H. Jokeit¹

¹Schweizerisches Epilepsie-Zentrum, Zürich

Abstract

Zusammenfassung

Antiepileptika (AED) verändern, basierend auf sehr unterschiedlichen Mechanismen, die Erregbarkeit von Nervenzellen und können so auch neurokognitive Prozesse beeinflussen. In den vergangenen Jahren wurden mehrere neue Antiepileptika zugelassen, die neben der Epilepsie auch zur Behandlung des neuropathischen Schmerzes und zur Stimmungsstabilisierung in der Psychiatrie eingesetzt werden. Es gibt jedoch nur wenige methodisch hinreichend kontrollierte Studien, die die neurokognitiven Wirkungen von Antiepileptika untersucht haben. Weiterhin fehlen Untersuchungen zu kognitiven Wirkungen neuer Antiepileptika in Kombinationstherapie mit älteren und anderen neuen Antiepileptika. Die Mehrzahl der neueren AED (Gabapentin, Lamotrigin, Levetiracetam, Oxcarbazepin) weisen gegenüber den älteren ein günstigeres neurokognitives Profil auf. Unter den neueren AED besteht bei Topiramat das höchste Risiko für kognitive Störwirkungen, die aber reversibel sind. Die Datenlage für Zonisamid ist für eine abschließende Beurteilung noch unzureichend, aber es verdichten sich Hinweise darauf, dass es häufiger kognitive Störwirkungen induziert als Gabapentin, Levetiracetam und Lamotrigin.

Abstracts

Antiepileptic drugs (AED) alter neuronal excitation levels and may lead to neurocognitive changes. In recent years, several new AEDs have been introduced which are additionally used to treat mood disorders, neuropathic pain and migraine. Generally, very few controlled trials have systematically examined the cognitive side effects of AEDs. In particular, polytherapy with the newer AEDs is under-investigated. In this paper we review the most relevant data pertaining to neurocognitive side effects of AEDs that are currently prescribed in Switzerland for the long-term treatment of epilepsies.

Schlüsselwörter

Antiepileptika - Nebenwirkungen - Kognition - Neuropsychologie - Epilepsie

Key words

antiepileptic drugs - side effects - cognition - neuropsychology - epilepsy

Full Text

References

Literatur

1 Marques C M, Caboclo L O, da Silva T I. et al . Cognitive decline in temporal lobe epilepsy due to unilateral hippocampal sclerosis. Epilepsy Behav. 2007; 10 477-485
2 Jokeit H, Schacher M. Neuropsychological aspects of type of epilepsy and etiological factors in adults. Epilepsy Behav. 2004; 5 (Suppl. 1) S14-20
3 Landmark C J. Targets for antiepileptic drugs in the synapse. Med Sci Monit. 2007; 13 RA1-7
4 Hessen E, Lossius M I, Reinvang I. et al . Influence of major antiepileptic drugs on attention, reaction time, and speed of information processing: results from a randomized, double-blind, placebo-controlled withdrawal study of seizure-free epilepsy patients receiving monotherapy. Epilepsia. 2006; 47 2038-2045
5 Gallassi R, Morreale A, Di Sarro R. et al . Cognitive effects of antiepileptic drug discontinuation. Epilepsia. 1992; 33 (Suppl. 6) S41-44
6 Chen Y, Chi Chow J, Lee I. Comparison the cognitive effect of anti-epileptic drugs in seizure-free children with epilepsy before and after drug withdrawal. Epilepsy Res. 2001; 44 65-70
7 Martin R, Meador K, Turrentine L. et al . Comparative cognitive effects of carbamazepine and gabapentin in healthy senior adults. Epilepsia. 2001; 42 764-771
8 Meador K J, Loring D W, Ray P G. et al . Differential cognitive effects of carbamazepine and gabapentin. Epilepsia. 1999; 40 1279-1285
9 Meador K J, Loring D W, Ray P G. et al . Differential cognitive and behavioral effects of carbamazepine and lamotrigine. Neurology. 2001; 56 1177-1182
10 Gillham R A, Williams N, Wiedmann K D. et al . Cognitive function in adult epileptic patients established on anticonvulsant monotherapy. Epilepsy Res. 1990; 7 219-225
11 Kang H C, Eun B L, Wu Lee C. et al . The effects on cognitive function and behavioral problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy. Epilepsia. 2007; 48 1716-1723
12 Aikia M, Jutila L, Salmenpera T. et al . Comparison of the cognitive effects of tiagabine and carbamazepine as monotherapy in newly diagnosed adult patients with partial epilepsy: pooled analysis of two long-term, randomized, follow-up studies. Epilepsia. 2006; 47 1121-1127
13 Dodrill C B, Arnett J L, Deaton R. et al . Tiagabine versus phenytoin and carbamazepine as add-on therapies: effects on abilities, adjustment, and mood. Epilepsy Res. 2000; 42 123-132
14 Read C L, Stephen L J, Stolarek I H. et al . Cognitive effects of anticonvulsant monotherapy in elderly patients: a placebo-controlled study. Seizure. 1998; 7 159-162
15 Kelly K M. Gabapentin. Antiepileptic mechanism of action. Neuropsychobiology. 1998; 38 139-144
16 Dodrill C B, Arnett J L, Hayes A G. et al . Cognitive abilities and adjustment with gabapentin: results of a multisite study. Epilepsy Res. 1999; 35 109-121
17 Salinsky M C, Binder L M, Oken B S. et al . Effects of gabapentin and carbamazepine on the EEG and cognition in healthy volunteers. Epilepsia. 2002; 43 482-490
18 Salinsky M C, Storzbach D, Spencer D C. et al . Effects of topiramate and gabapentin on cognitive abilities in healthy volunteers. Neurology. 2005; 64 792-798
19 Mortimore C, Trimble M, Emmers E. Effects of gabapentin on cognition and quality of life in patients with epilepsy. Seizure. 1998; 7 359-364
20 Leach J P, Girvan J, Paul A. et al . Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy. J Neurol Neurosurg Psychiatry. 1997; 62 372-376
21 Hurley S C. Lamotrigine update and its use in mood disorders. Ann Pharmacother. 2002; 36 860-873
22 Smith D, Baker G, Davies G. et al . Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia. 1993; 34 312-322
23 Pressler R M, Binnie C D, Coleshill S G. et al . Effect of lamotrigine on cognition in children with epilepsy. Neurology. 2006; 66 1495-1499
24 Zoccali R, Muscatello M R, Bruno A. et al . The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study. Schizophr Res. 2007; 93 109-116
25 Placidi F, Marciani M G, Diomedi M. et al . Effects of lamotrigine on nocturnal sleep, daytime somnolence and cognitive functions in focal epilepsy. Acta Neurol Scand. 2000; 102 81-86
26 Aldenkamp A P, Arends J, Bootsma H P. et al . Randomized double-blind parallel-group study comparing cognitive effects of a low-dose lamotrigine with valproate and placebo in healthy volunteers. Epilepsia. 2002; 43 19-26
27 Meador K J, Loring D W, Vahle V J. et al . Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers. Neurology. 2005; 64 2108-2114
28 Werz M A, Schoenberg M R, Meador K J. et al . Subjective preference for lamotrigine or topiramate in healthy volunteers: relationship to cognitive and behavioral functioning. Epilepsy Behav. 2006; 8 181-191
29 Smith M E, Gevins A, McEvoy L K. et al . Distinct cognitive neurophysiologic profiles for lamotrigine and topiramate. Epilepsia. 2006; 47 695-703
30 Blum D, Meador K, Biton V. et al . Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. Neurology. 2006; 67 400-406
31 Zhou B, Zhang Q, Tian L. et al . Effects of levetiracetam as an add-on therapy on cognitive function and quality of life in patients with refractory partial seizures. Epilepsy Behav. 2008; 12 305-310
32 Ciesielski A S, Samson S, Steinhoff B J. Neuropsychological and psychiatric impact of add-on titration of pregabalin versus levetiracetam: a comparative short-term study. Epilepsy Behav. 2006; 9 424-431
33 Gomer B, Wagner K, Frings L. et al . The influence of antiepileptic drugs on cognition: a comparison of levetiracetam with topiramate. Epilepsy Behav. 2007; 10 486-494
34 Neyens L G, Alpherts W C, Aldenkamp A P. Cognitive effects of a new pyrrolidine derivative (levetiracetam) in patients with epilepsy. Prog Neuropsychopharmacol Biol Psychiatry. 1995; 19 411-419
35 Meador K J, Gevins A, Loring D W. et al . Neuropsychological and neurophysiologic effects of carbamazepine and levetiracetam. Neurology. 2007; 69 2076-2084
36 Mecarelli O, Vicenzini E, Pulitano P. et al . Clinical, cognitive, and neurophysiologic correlates of short-term treatment with carbamazepine, oxcarbazepine, and levetiracetam in healthy volunteers. Ann Pharmacother. 2004; 38 1816-1822
37 Vajda F J. New antiepileptic drugs. J Clin Neurosci. 2000; 7 88-101
38 Tzitiridou M, Panou T, Ramantani G. et al . Oxcarbazepine monotherapy in benign childhood epilepsy with centrotemporal spikes: a clinical and cognitive evaluation. Epilepsy Behav. 2005; 7 458-467
39 Donati F, Gobbi G, Campistol J. et al . The cognitive effects of oxcarbazepine versus carbamazepine or valproate in newly diagnosed children with partial seizures. Seizure. 2007; 16 670-679
40 Salinsky M C, Spencer D C, Oken B S. et al . Effects of oxcarbazepine and phenytoin on the EEG and cognition in healthy volunteers. Epilepsy Behav. 2004; 5 894-902
41 Aikia M, Kalviainen R, Sivenius J. et al . Cognitive effects of oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy: one year follow-up. Epilepsy Res. 1992; 11 199-203
42 Twyman R E, Rogers C J, Macdonald R L. Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital. Ann Neurol. 1989; 25 213-220
43 Riva D, Devoti M. Discontinuation of phenobarbital in children: effects on neurocognitive behavior. Pediatr Neurol. 1996; 14 36-40
44 Tonekaboni S H, Beyraghi N, Tahbaz H S. et al . Neurocognitive effects of phenobarbital discontinuation in epileptic children. Epilepsy Behav. 2006; 8 145-148
45 Meador K J, Loring D W, Moore E E. et al . Comparative cognitive effects of phenobarbital, phenytoin, and valproate in healthy adults. Neurology. 1995; 45 1494-1499
46 Chen Y J, Kang W M, So W C. Comparison of antiepileptic drugs on cognitive function in newly diagnosed epileptic children: a psychometric and neurophysiological study. Epilepsia. 1996; 37 81-86
47 Jokeit H, Kramer G, Ebner A. Do antiepileptic drugs accelerate forgetting?. Epilepsy Behav. 2005; 6 430-432
48 Yaari Y, Selzer M E, Pincus J H. Phenytoin: mechanisms of its anticonvulsant action. Ann Neurol. 1986; 20 171-184
49 Gallassi R, Morreale A, Lorusso S. et al . Cognitive effects of phenytoin during monotherapy and after withdrawal. Acta Neurol Scand. 1987; 75 258-261
50 Gallassi R, Morreale A, Lorusso S. et al . Carbamazepine and phenytoin. Comparison of cognitive effects in epileptic patients during monotherapy and withdrawal. Arch Neurol. 1988; 45 892-894
51 Pulliainen V, Jokelainen M. Comparing the cognitive effects of phenytoin and carbamazepine in long-term monotherapy: a two-year follow-up. Epilepsia. 1995; 36 1195-1202
52 Duncan J S, Shorvon S D, Trimble M R. Effects of removal of phenytoin, carbamazepine, and valproate on cognitive function. Epilepsia. 1990; 31 584-591
53 Brown E S, Stuard G, Liggin J D. et al . Effect of phenytoin on mood and declarative memory during prescription corticosteroid therapy. Biol Psychiatry. 2005; 57 543-548
54 Craig I, Tallis R. Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single-blind randomized comparative study. Epilepsia. 1994; 35 381-390
55 Beenen L F, Lindeboom J, Kasteleijn-Nolst Trenite D G. et al . Comparative double blind clinical trial of phenytoin and sodium valproate as anticonvulsant prophylaxis after craniotomy: efficacy, tolerability, and cognitive effects. J Neurol Neurosurg Psychiatry. 1999; 67 474-480
56 Aldenkamp A P, Alpherts W C, Diepman L. et al . Cognitive side-effects of phenytoin compared with carbamazepine in patients with localization-related epilepsy. Epilepsy Res. 1994; 19 37-43
57 Aldenkamp A P, Alpherts W C, Blennow G. et al . Withdrawal of antiepileptic medication in children – effects on cognitive function: The Multicenter Holmfrid Study. Neurology. 1993; 43 41-50
58 Pulliainen V, Jokelainen M. Effects of phenytoin and carbamazepine on cognitive functions in newly diagnosed epileptic patients. Acta Neurol Scand. 1994; 89 81-86
59 Dodrill C B, Troupin A S. Neuropsychological effects of carbamazepine and phenytoin: a reanalysis. Neurology. 1991; 41 141-143
60 Dodrill C B, Temkin N R. Motor speed is a contaminating factor in evaluating the „cognitive” effects of phenytoin. Epilepsia. 1989; 30 453-457
61 Taylor C P, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007; 73 137-150
62 Hindmarch I, Trick L, Ridout F. A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers. Psychopharmacology (Berl). 2005; 183 133-143
63 Macdonald R L, Kelly K M. Antiepileptic drug mechanisms of action. Epilepsia. 1995; 36 (Suppl. 2) S2-12
64 White H S. Molecular pharmacology of topiramate: managing seizures and preventing migraine. Headache. 2005; 45 (Suppl. 1) S48-56
65 Fritz N, Glogau S, Hoffmann J. et al . Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy Behav. 2005; 6 373-381
66 Lee H W, Jung D K, Suh C K. et al . Cognitive effects of low-dose topiramate monotherapy in epilepsy patients: A 1-year follow-up. Epilepsy Behav. 2006; 8 736-741
67 Romigi A, Cervellino A, Marciani M G. et al . Cognitive and psychiatric effects of topiramate monotherapy in migraine treatment: an open study. Eur J Neurol. 2008; 15 190-195
68 Aldenkamp A P, Baker G, Mulder O G. et al . A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia. 2000; 41 1167-1178
69 de Araujo Filho G M, Pascalicchio T F, Lin K. et al . Neuropsychiatric profiles of patients with juvenile myoclonic epilepsy treated with valproate or topiramate. Epilepsy Behav. 2006; 8 606-609
70 Kockelmann E, Elger C E, Helmstaedter C. Significant improvement in frontal lobe associated neuropsychological functions after withdrawal of topiramate in epilepsy patients. Epilepsy Res. 2003; 54 171-178
71 Kockelmann E, Elger C E, Helmstaedter C. Cognitive profile of topiramate as compared with lamotrigine in epilepsy patients on antiepileptic drug polytherapy: relationships to blood serum levels and comedication. Epilepsy Behav. 2004; 5 716-721
72 Martin R, Kuzniecky R, Ho S. et al . Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology. 1999; 52 321-327
73 Meador K J, Loring D W, Hulihan J F. et al . Differential cognitive and behavioral effects of topiramate and valproate. Neurology. 2003; 60 1483-1488
74 Rosenberg G. The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees?. Cell Mol Life Sci. 2007; 64 2090-2103
75 Thompson P J, Trimble M R. Sodium valproate and cognitive functioning in normal volunteers. Br J Clin Pharmacol. 1981; 12 819-824
76 Gallassi R, Morreale A, Lorusso S. et al . Cognitive effects of valproate. Epilepsy Res. 1990; 5 160-164
77 Dikmen S S, Machamer J E, Winn H R. et al . Neuropsychological effects of valproate in traumatic brain injury: a randomized trial. Neurology. 2000; 54 895-902
78 Senturk V, Goker C, Bilgic A. et al . Impaired verbal memory and otherwise spared cognition in remitted bipolar patients on monotherapy with lithium or valproate. Bipolar Disord. 2007; 9 (Suppl. 1) 136-144
79 Helmstaedter C, Wagner G, Elger C E. Differential effects of first antiepileptic drug application on cognition in lesional and non-lesional patients with epilepsy. Seizure. 1993; 2 125-130
80 Siren A, Kylliainen A, Tenhunen M. et al . Beneficial effects of antiepileptic medication on absence seizures and cognitive functioning in children. Epilepsy Behav. 2007; 11 85-91
81 Wilensky A J, Friel P N, Ojemann L M. et al . Zonisamide in epilepsy: a pilot study. Epilepsia. 1985; 26 212-220
82 Berent S, Sackellares J C, Giordani B. et al . Zonisamide (CI-912) and cognition: results from preliminary study. Epilepsia. 1987; 28 61-67
83 Ojemann L M, Ojemann G A, Dodrill C B. et al . Language Disturbances as Side Effects of Topiramate and Zonisamide Therapy. Epilepsy Behav. 2001; 2 579-584
84 Park S P, Hwang Y H, Lee H W. et al . Long-term cognitive and mood effects of zonisamide monotherapy in epilepsy patients. Epilepsy Behav. 2008; 12 102-108
85 Ketter T A, Post R M, Theodore W H. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology. 1999; 53 S53-67
86 Cochrane H C, Marson A G, Baker G A. et al . Neuropsychological outcomes in randomized controlled trials of antiepileptic drugs: a systematic review of methodology and reporting standards. Epilepsia. 1998; 39 1088-1097

PD Dr. Hennric Jokeit

Schweizerisches Epilepsie-Zentrum

Bleulerstr. 60

8008 Zürich, Schweiz

Email: h.jokeit@swissepi.ch